Management of Hepatitis C Infection
Summary
- Ledipasvir/sofosbuvir is approved for use in patients with compensated cirrhosis[FDA Ledipasvir/Sofosbuvir] and has demonstrated efficacy in this population[Afdhal 2014a; Afdhal 2014b]
- Safety and efficacy of ledipasvir/sofosbuvir has been investigated in patients with decompensated cirrhosis[Charlton 2015b]
- Observational studies of real-world use show high SVR rates with ledipasvir/sofosbuvir with or without ribavirin in patients with cirrhosis, including decompensated cirrhosis[Tapper 2017; Terrault 2016; Backus 2016]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Hepatitis C-Treatment